Combating Fungal resistance: Why Dermatophytosis Diagnosis​ and ⁢Treatment Demand Precision

George Washington University Expert Highlights Critical Need for Accurate Diagnosis and Antifungal Stewardship

Dermatophytosis, a common yet ‌often underestimated group of fungal skin infections, requires a more focused ‌approach due to the escalating threat of antifungal resistance. Dr. [insert Name of Friedman, if available, otherwise use “a leading expert”], Chair of Dermatology, Residency Program ‌Director, Director of Translational Research, and Director of the ‌Supportive Oncodermatology Program at the george Washington University school of Medicine & Health, emphasized the critical importance of recognizing and accurately treating these infections.

The Overlooked Threat of ‌Dermatophytosis

“Dermatophytosis, which encompasses a wide array of clinical cutaneous‍ infections associated with dermatophyte infections, is super common, but is not commonly discussed because it just isn’t ‘sexy,'” stated Dr. Friedman. He acknowledged the public’s general disinterest in fungal infections but stressed the imperative to address the issue ‍head-on. “We need to be able to make the right diagnosis, but also consider the potential for anti-fungal ⁣resistance ‌if we don’t treat the right thing, or if ​we’re not thoughtful about how we use our anti-fungals, of which we sadly don’t have a huge amount.”

Beyond Clinical Inspection: The Power of diagnostic Tools

Dr. Friedman underscored that relying solely on clinical inspection for diagnosing dermatophytosis ⁤is insufficient. He strongly advocated for the integration of diagnostic tools such as ⁣potassium hydroxide (KOH) preps, scrapings, cultures,⁢ and biopsies to ensure accurate⁤ identification ‍and effective treatment of ⁣fungal infections.

“I know we‌ pride ourselves as master diagnosticians, but we⁤ have proven time and again in the published literature that clinical inspection is not enough,” Dr. Friedman ‍explained. “Use my favorite tool of all time, your‌ potassium hydroxide⁤ prep. I realize there are some limitations with CLIA certification, but this very simple tool can be the distinguisher‌ between calling something a dermatophyte infection or⁣ something⁣ primary inflammatory. By defining ⁤the ⁢disease, you can purposely select ‌the correct treatment regimen, which will ​then make your patient happy and will prevent fungi from developing resistance to the limited things‍ we have.”

The Growing Challenge of Antifungal Resistance

The expert issued a stern warning regarding the increasing resistance to antifungal medications, notably azole antifungals like econazole and fluconazole. He highlighted the necessity for diligent antifungal stewardship, drawing parallels to the established practices of antibacterial stewardship, especially given the limited pipeline of new antifungal treatments.

“When we think about our anti-fungal armamentarium, most of them are what‌ are called static,”⁢ Dr.‍ Friedman ⁢elaborated. “They are inhibiting an enzyme or something that’s needed for cell survival. And when you are inhibiting one ⁤thing, the problem is, the fungus among us can become kind of clever and pivot.That, in essence, is where resistance occurs, where one surviving cell has managed ‍to shift the narrative and utilize other machinery ⁢to survive.And then it passes that details through its friends…and then we have an anti-fungal that’s rendered useless.”

For those ‍seeking further insights into the topics ⁢discussed by Dr. Friedman regarding tinea infections,his complete video ⁣interview is available. For more information on‍ related dermatological advancements, explore our coverage of the latest DERM 2025 conference.**

The quotes in this article‍ have been edited for clarity.

Dr. Friedman has ​previously reported serving as a consultant ‍to Dermira, Eli lilly and Company,‌ Encore Dermatology Inc, ‍Exeltis, Galderma, IntraDerm, Johnson and Johnson, Oculus Innovative Sciences, Pfizer Inc, and⁢ Sanovaworks.*